InDex Pharmaceuticals Q1 2023: Our comments
Research Update
2023-05-25
08:05
Redeye comments on InDex Pharmaceuticals following its Q1 2023 report. We consider the report undramatic and do not make any significant adjustments. Again, we highlight that InDex trades at a notable discount compared to its cash position.
FE
Filip Einarsson
Disclosures and disclaimers